Preparation method of ritonavir

A technology for ritonavir and compound, applied in the field of preparation of ritonavir, can solve problems such as unfavorable scale-up production, low yield, high price, etc., and achieves low cost, easy large-scale production, and good application prospect Effect

Pending Publication Date: 2019-02-22
贵州永诺菲特生物制药有限公司
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The p-nitrophenyl chloroformate used in this method is very active, so that the yield in the first two steps is not high, only...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of ritonavir
  • Preparation method of ritonavir
  • Preparation method of ritonavir

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0043] Such as figure 1 Shown, the preparation method of a kind of ritonavir of the present invention comprises the following steps:

[0044] Step 1, the preparation of compound III, the reaction scheme is as follows:

[0045]

[0046] a. Add (2-isopropylthiazol-4-yl)-nitrogen-methylmethylamine 50.0 g (0.294 mol, 1.0 eq), (S)-3-methyl-2-[(2,2,2 -Trichloroethoxy)formamide]butyric acid 86.0 g (0.294 mol, 1.0 eq), triethylamine 38.6 g (0.382 mol, 1.3 eq) and tetrahydrofuran 250 mL were added to the reaction flask, and the temperature was raised to 50-60°C;

[0047] b, start the reaction until the reaction 6h to the disappearance of raw materials;

[0048] c. After the reaction is completed, cool down to room temperature, pour into 500 mL of 1N hydrochloric acid, and extract with 250 mL of ethyl acetate × 2;

[0049] d. Combine the organic phases, wash with 300 mL of water, and then wash with 300 mL of saturated brine;

[0050] e. Concentrate under reduced pressure to dryne...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicine, in particular to a preparation method of ritonavir. According to the preparation method of the ritonavir, (2-isopropyl thiazole-4-yl)-nitrogen-methyl methylamine is taken as a raw material, and the ritonavir is synthesized through a three-step reaction; a urea bond is built by trichloroethanol chloroformate, paratoluensulfonyl chloride which is cheap and easy to obtain is adopted as a condensing agent for amide, the ritonavir is synthesized with the high yield, and the yield of the ritonavir is 79%; and compared with an existing preparation method, the preparation method has the advantages of low cost, environment friendliness, easy scale production and the like, and has good application prospects.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a preparation method of ritonavir. Background technique [0002] At present, the design of anti-HIV drugs is mainly aimed at the three key enzymes in the HIV replication cycle, namely reverse transcriptase, protease, integrase, and HIV invasion process. According to the different drug targets, it can be divided into six categories, namely: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors ( EIs), integrase inhibitors (IIs) and CCR5 receptor antagonists, etc. In 1987, the first anti-HIV drug Zidovudine (AZT), which belongs to nucleoside reverse transcriptase inhibitors, was launched on the market. Saquinavir is the world's first approved protease inhibitor. It was developed by Roche in 1995 and approved by the FDA. Good results have been obtained, and thus the era of combin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D277/28
CPCC07D277/28
Inventor 冉刚任旭张毅宁兆伦周钟
Owner 贵州永诺菲特生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products